Lorazepam in status epilepticus

J. E. Walker, R. W. Homan, Michael Vasko, I. L. Crawford, R. D. Bell, W. G. Tasker

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Lorazepam, a dichloro-3-hydroxy-1,4-benzodiazepine, has been shown to be a potent anticonvulsant in animal models of epilepsy and has minimal depressant effects on respiration and circulation in humans. The effects of this compound were studied in status epilepticus. Twenty-five patients were given intravenous lorazepam during status epilepticus of varying cause. Four or 8 mg of the drug controlled status in 22 of the 25 patients. Although single seizures recurred in 5 of the 22 patients, none experienced recurrence of status during a prolonged follow-up period. Transient respiratory arrest occurred in 1 patient, but no other significant complications were observed. Studies of plasma drug levels suggest that most patients attain good seizure control at concentrations between 30 and 100 ng per milliliter. Clinical observations indicate that repetitive injections are not required for continuing control of seizures in patients whose seizures are initially controlled. Lorazepam appears to be an effective and safe drug for treatment of status epilepticus, with a duration of control longer than that achieved with diazepam.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalAnnals of Neurology
Volume6
Issue number3
StatePublished - 1979
Externally publishedYes

Fingerprint

Lorazepam
Status Epilepticus
Seizures
Epilepsy
Pharmaceutical Preparations
Diazepam
Anticonvulsants
Respiration
Animal Models
Recurrence
Injections

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Walker, J. E., Homan, R. W., Vasko, M., Crawford, I. L., Bell, R. D., & Tasker, W. G. (1979). Lorazepam in status epilepticus. Annals of Neurology, 6(3), 207-213.

Lorazepam in status epilepticus. / Walker, J. E.; Homan, R. W.; Vasko, Michael; Crawford, I. L.; Bell, R. D.; Tasker, W. G.

In: Annals of Neurology, Vol. 6, No. 3, 1979, p. 207-213.

Research output: Contribution to journalArticle

Walker, JE, Homan, RW, Vasko, M, Crawford, IL, Bell, RD & Tasker, WG 1979, 'Lorazepam in status epilepticus', Annals of Neurology, vol. 6, no. 3, pp. 207-213.
Walker JE, Homan RW, Vasko M, Crawford IL, Bell RD, Tasker WG. Lorazepam in status epilepticus. Annals of Neurology. 1979;6(3):207-213.
Walker, J. E. ; Homan, R. W. ; Vasko, Michael ; Crawford, I. L. ; Bell, R. D. ; Tasker, W. G. / Lorazepam in status epilepticus. In: Annals of Neurology. 1979 ; Vol. 6, No. 3. pp. 207-213.
@article{fb9759b7998545aa857b50d4d147c787,
title = "Lorazepam in status epilepticus",
abstract = "Lorazepam, a dichloro-3-hydroxy-1,4-benzodiazepine, has been shown to be a potent anticonvulsant in animal models of epilepsy and has minimal depressant effects on respiration and circulation in humans. The effects of this compound were studied in status epilepticus. Twenty-five patients were given intravenous lorazepam during status epilepticus of varying cause. Four or 8 mg of the drug controlled status in 22 of the 25 patients. Although single seizures recurred in 5 of the 22 patients, none experienced recurrence of status during a prolonged follow-up period. Transient respiratory arrest occurred in 1 patient, but no other significant complications were observed. Studies of plasma drug levels suggest that most patients attain good seizure control at concentrations between 30 and 100 ng per milliliter. Clinical observations indicate that repetitive injections are not required for continuing control of seizures in patients whose seizures are initially controlled. Lorazepam appears to be an effective and safe drug for treatment of status epilepticus, with a duration of control longer than that achieved with diazepam.",
author = "Walker, {J. E.} and Homan, {R. W.} and Michael Vasko and Crawford, {I. L.} and Bell, {R. D.} and Tasker, {W. G.}",
year = "1979",
language = "English",
volume = "6",
pages = "207--213",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Lorazepam in status epilepticus

AU - Walker, J. E.

AU - Homan, R. W.

AU - Vasko, Michael

AU - Crawford, I. L.

AU - Bell, R. D.

AU - Tasker, W. G.

PY - 1979

Y1 - 1979

N2 - Lorazepam, a dichloro-3-hydroxy-1,4-benzodiazepine, has been shown to be a potent anticonvulsant in animal models of epilepsy and has minimal depressant effects on respiration and circulation in humans. The effects of this compound were studied in status epilepticus. Twenty-five patients were given intravenous lorazepam during status epilepticus of varying cause. Four or 8 mg of the drug controlled status in 22 of the 25 patients. Although single seizures recurred in 5 of the 22 patients, none experienced recurrence of status during a prolonged follow-up period. Transient respiratory arrest occurred in 1 patient, but no other significant complications were observed. Studies of plasma drug levels suggest that most patients attain good seizure control at concentrations between 30 and 100 ng per milliliter. Clinical observations indicate that repetitive injections are not required for continuing control of seizures in patients whose seizures are initially controlled. Lorazepam appears to be an effective and safe drug for treatment of status epilepticus, with a duration of control longer than that achieved with diazepam.

AB - Lorazepam, a dichloro-3-hydroxy-1,4-benzodiazepine, has been shown to be a potent anticonvulsant in animal models of epilepsy and has minimal depressant effects on respiration and circulation in humans. The effects of this compound were studied in status epilepticus. Twenty-five patients were given intravenous lorazepam during status epilepticus of varying cause. Four or 8 mg of the drug controlled status in 22 of the 25 patients. Although single seizures recurred in 5 of the 22 patients, none experienced recurrence of status during a prolonged follow-up period. Transient respiratory arrest occurred in 1 patient, but no other significant complications were observed. Studies of plasma drug levels suggest that most patients attain good seizure control at concentrations between 30 and 100 ng per milliliter. Clinical observations indicate that repetitive injections are not required for continuing control of seizures in patients whose seizures are initially controlled. Lorazepam appears to be an effective and safe drug for treatment of status epilepticus, with a duration of control longer than that achieved with diazepam.

UR - http://www.scopus.com/inward/record.url?scp=0018292282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018292282&partnerID=8YFLogxK

M3 - Article

C2 - 43112

AN - SCOPUS:0018292282

VL - 6

SP - 207

EP - 213

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -